glp 1 agonist effects GLP-1 Receptor Agonists GLP-1 receptor agonists: Optimising nutritional

Description

doi:10.1111/cns.12866 de la Monte SM, Wands JR

As a novel antidiabetic agent, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are seeing an increasing application in the management of patients with T2DM, given their remarkable efficacy in regulating blood sugar levels without posing an elevated risk of hypoglycemic episodes or weight gain ( However, safety concerns have persisted for years regarding the pancreatic effects of GLP-1 RAs

The cardiorenal effects of both GLP-1RA and SGLT-2 inhibitors can be summarized as follows: GLP-1RA have moderate benefits on MACE (major cardiovascular events), may reduce all-cause mortality and hospitalization for HF (HHF), and have a robust effect in reducing the incidence of macroalbuminuria [12]

Cardiac electrophysiological alterations and clinical response in cardiac resynchronization therapy with a defibrillator treated patients affected by metabolic syndrome